. The tumours in these eight patients consisted of gastrinomas (n=3), neuroendocrine tumours of the small intestine (n=3), and neuroendocrine pancreatic tumours (n=2). In four of 12 patients negative SRS results were obtained (Table) .
10.0
These four patients suffered from insulinoma (n= 1), atypical carcinoid (liver metastasis and 5 unknown primary tumour, n=1), and func-< tional neuroendocrine ileal tumours (n= 2), one with metastases of the liver and ovary and one with only an ovarian metastasis. Although the liver metastasis was positive by SRS, the metastases to the ovaries, which were 3 or 4 cm Figure 1 . larisation, occupation of the ligand binding site, endocytotic rate, etc add to the positive or negative signal in SRS. In addition to SST-28 binding, high levels of octreotide binding were found in all gastrinoma tissues (Fig 2) . Figure 1 shows the RT-PCR data obtained from tumour tissue samples of all patients r24 and to a lesser negative by SRS. Two patients were negative cotide as well as both by SRS and octreotide autoradiography. ST-28 as radioli-In one of these patients (atypical carcinoid), re found in most mRNA levels for sstrs were comparably low in 1-4). However, comparison to SRS positive tumour tissues the insulinoma such as gastrinomas (see below). In the other binding as deter-patient (insulinoma 1), moderate amounts of igs 1 and 5 C-F). sstrl and sstr2 mRNAs but high levels of sstr4 e SRS results in mRNA were detected at a qualitative level (see t, in two patients above). This suggests that SRS negative had been missed tumours do not synthesise sufficient receptor and were positive protein for adequate visualisation. Only sstr y (Fig 1) . Inter-subtype 1 and 2 mRNAs were consistently of one of these detected at high levels in all SRS negative cases le binding sites that showed positive octreotide autoradiodiography. This graphy. Interestingly, in one patient with a the metastatic neuroendocrine ileal tumour metastatic to the as tumour vascu-liver and the ovary, the sstrl and 2 transcripts were observed in both metastases (Fig 1) . As B already pointed out, SRS was only positive in 10.0 the liver in this patient. The positive autoradiography with octreotide in both metastases (liver and ovary) probably accounts for the I _ sstr2 subtype.32
In vivo binding of octreotide to sstr subtype 2 is especially supported by one patient with an < serotonin producing pancreatic tumour _ (PNET 2), in whom octreotide autoradiogra-_ phy was positive and only sstr subtype 2 mRNA was found by RT-PCR (Fig 3) . Gastrinomas, known to be almost always positive by in vitro autoradiography and by 1.0 SRS, showed consistently high expression of sstr subtypes 2 and 5 mRNAs (Fig 2) (1 1 of 13), sstr5 (seven of 13), and sstr4 (seven of 13). sstr subtype 3 transcripts were detected only at low levels or not at all throughout all tissue samples studied (six of 13) (Figs 1-3 Fig 1) . Interestingly liver metastases were positive by SRS whereas an ovarian metastasis was negative in the same patient ( (Fig 1) . However, in two other patients ovarian metastases that had been missed by SRS despite their sizes of 3 or 4 cm were positive for octreotide and SST binding by in vitro autoradiography (Fig 1) . This indicates that at least some neuroendocrine tumour lesions are false negative by SRS. Since one of the two patients with SRS negative ovarian metastases had liver metastases that were positive by SRS, we suggest that SRS positivity may depend not only on the expression pattern and expression levels ofvarious sstr subtypes (see below) but also on the blood supply, locally high concentrations of endogenous SST, as well as down regulation of SST binding sites by various factors (for example, corticosteroids). Based on our autoradiographic and SRS findings, we expected to find at least one of the five subtypes in 10 out of 12 patients studied by RT-PCR. Semiquantitative RT-PCR analysis of sstr expression in the various neuroendocrine tumour tissues showed that all contained high levels of sstr2 mRNA, except the two tissues mentioned above that were true negative by SRS and autoradiography (Figs 1-3 (Fig 3) and since the tumour had been positive by SRS and autoradiography, we consider this the first direct evidence for high affinity binding sites of octreotide to sstr2 in vivo.
Gastrinomas generally exhibit high uptake of radiolabelled octreotide in vivo and show high incidence of sstr by autoradiography.4 9 All of our gastrinoma patients were strongly positive by SRS, and tumour tissues of these patients contained both sstr2 and sstr5 transcripts (Fig 2) . It is noteworthy that only sstr2 and sstr5 mRNAs were detected in tumour tissue of one of the three gastrinoma patients (Fig 2) . Since the intensity of receptor scintigram in this patient was similar to that of the two other gastrinoma patients expressing additional sstr subtype mRNAs, we suggest that in addition to sstr2 sstr5 may also bind octreotide in vivo, since both subtypes possess reported high affinity binding sites for octreotide at least in vitro.24 Other sstr subtypes seem to be less important for the positivity of SRS.
Interestingly, in one patient with a primary, ileal neuroendocrine tumour metastatic to the liver and ovary, only sstrl and 2 were found in all tissues studied (Fig 1) , which supports the suggestion3 25 that the expression patterns of sstr subtypes may be conserved during the metastatic process in a tumour specific fashion. Analysis of the expression of the mRNAs of all sstr subtypes in tumour tissues (n= 13) from all patients (n= 12) investigated showed a heterogeneous pattern, sstr2 was most frequently found (13 of 13), followed by sstrl (11 of 13), sstr5 (seven of 13) and sstr4 (seven of 13). Expression of sstr3 transcripts was the least frequently detected (six of 13) and expression levels were comparably low.
Analysis Reply EDITOR,-We are grateful for the interest Professor M J S Langman took in our paper and regret that it has obviously given rise to some misunderstanding.
The preselection of patients diagnosed for drug induced acute pancreatitis was made by the centres where they had been treated. All charts of patients considered to fall into this group were reviewed by us. We looked only for drugs, however, currently held responsible for inducing acute pancreatitis. It is possible that in the 135 patients with acute pancreatitis of unknown aetiology drugs had been given still unknown to induce acute pancreatitis and thus the incidence of this aetiology might be somewhat higher.
Prospective studies help to answer open questions but logistic realities pose problems. The two questions at issue are: how frequently does the application of a certain drug lead to acute pancreatitis and, how frequent is drug induced acute pancreatitis among all patients with acute pancreatitis?
The first question is impossible to answer. In view of the great number of patients receiving drugs such as frusemide and oestrogen, it would be impossible to follow up all of them for signs and symptoms of acute pancreatitis. Even the second question is difficult to answer. To make quite sure that the suspected drug has really induced the disease, a re-exposure to the drug in question is necessary, something ethically difficult to justify.
The message of our paper was simply that drug induced acute pancreatitis is probably rare and that the disease usually takes a benign course. Such a retrospective evaluation in a substantial number of patients has not been done before. 
